Ucbbiopharma Srl

Ucb Pharma, S.a.

Ucb Biopharma Sprl

Stephen Edward Rapecki

Ralph Adams

Andrew George Popplewell

Helene Margaret Finney

Michael John Wright

Kerry Louise Tyson

John Robert Porter

Graham John Warrellow

Boris Kroeplien

Timothy John Norman

Alastair Lawson

James Philip O'Connell

Simon Peter Tickle

Daniel John Lightwood

Mark Daniel Calmiano

William Ross Pitt

Tracy Lynn Arakaki

Paul Alfred Smith

Alex Buntin Burgin

David Andreas Schubert

Adam Samuel Platt

Mara Fortunato

David Robert Rainey

Jon Leigh Rundle

James Philip O'connell

Rikki Peter Alexander

Daniel Christopher Brookings

Martyn Kim Robinson

David James McMillan

Rebecca Jayne Munro

Gillian Fairfull Watt

Rebecca Jayne Wootton

Gillian Sairfull Watt

Mark Ian Christie

Richard James Mead

David James Mcmillan

Helen Margaret Finney

David Alan Cook

The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

Antibody molecules which bind CD22

The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.

Antibody molecules which bind CD45

A new, stable trimeric TNF&#x3b1; structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF&#x3b1;/TNFR1 interaction. Membrane-bound TNF&#x3b1; is not affected in its ability to signal through TNFR2, and thus the new structure of TNF&#x3b1; may be used in therapies which do not significantly raise the risk of infection or malignancy.

Method of identifying potential inhibitors of APO TNF&#x3b1; trimers

The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.

Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy

It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.

Method for identifying a modulator of the TNF&#x3b1; or CD40L interaction with their cognate receptors

The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.

Molecules with specificity for CD79 and CD22

The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.

Methods of identifying signaling modulators of the trimeric TNFa

The present invention relates to a method of identifying, separating and characterizing a cell or a population of cells, by capturing at the cell surface, secreted soluble substances (such as an immunoglobulin) that cell or population of cell secrete. This is achieved by combing on a heterodimerically-tethered multispecific protein complex combining a binding specificity for the secreted molecule and a binding specificity for a surface antigen specific for that cell or population of cells. This method may be used in research and experimental purposes, such as patients' stratification in preparation of clinical trials or personalized therapies by identifying cell populations relevant to a pathology and/or prognosis.

Method employing bispecific antibodies

The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.

Molecules with specificity for CD45 and CD79

Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers

TNF receptor signaling modulator assay

The present disclosure relates to antibody molecules comprising a binding domain specific to CD79, said binding domain comprising SEQ ID NO: 1, 2, 3 or 4, and/or SEQ ID NO: 5, 6 and 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

Antibody molecules which bind CD79

Growing community of inventors

Slough, United Kingdom

Stephen Edward Rapecki